Reframing Alzheimer’s Disease: Prof. Ashley Bush on a Metal–Energy–Lipid Framework of Neurodegeneration
On April 12-13, 2026, during the Element Science Global Summit 2026 held at the First Hospital of Jilin University, Changchun, China, the Editorial Office of Element conducted a special interview with Prof. Ashley Bush from the University of Melbourne, Australia, Associate Editor for Element.
The interview focused on recent advances in metal biology and neurodegenerative disease research, with particular emphasis on iron and copper dyshomeostasis, mitochondrial dysfunction, ferroptosis, Alzheimer's disease mechanisms, biomarker development, and metal-targeted therapeutic strategies.
During the interview, Prof. Bush discussed several key topics, including the metal–energy–lipid framework of Alzheimer's disease, the causal or amplifying role of ferroptosis in neurodegeneration, and the current limitations of metal-targeted therapies such as deferiprone. He also highlighted the importance of therapeutic timing, targeting specificity, and patient stratification, as well as the need for systems-level models integrating ApoE4, tau pathology, metal imbalance, mitochondrial stress, and emerging biomarkers such as plasma p-tau217. As an Associate Editor of Element, he further emphasized the importance of publishing conceptually transformative studies with strong mechanistic depth and translational relevance.
Interview Questions:
Q1: Your work integrates iron, copper, mitochondrial dysfunction, and ferroptosis in Alzheimer's disease - do you think the field is converging toward a unified metal–energy–lipid framework of neurodegeneration, or are these still fundamentally separate pathological axes?
Q2: Given your recent contributions linking ferroptosis and metabolic stress in neurodegeneration, do you view ferroptosis as a primary causal mechanism in disease initiation, or more as an amplifying downstream consequence of metal dyshomeostasis?
Q3: The deferiprone clinical trial in Alzheimer's disease suggests that simply reducing brain iron is not sufficient for strong clinical efficacy - what do you think is currently missing in metal-targeted therapeutic strategies, such as timing, targeting specificity, or patient stratification?
Q4: With growing evidence linking ApoE4, tau pathology, iron/copper imbalance, mitochondrial stress, and emerging biomarkers like plasma p-tau217, do you think Alzheimer's disease is moving toward a systems-level definition that replaces single-cause hypotheses entirely?
Q5: As an Associate Editor of Element, what strategies can Element adopt to attract and retain truly transformative papers, rather than papers that are merely technically solid but lack conceptual depth or broader relevance?
About Prof. Ashley Bush:
Ashley Bush (MBBS, DPM, FRANZCP, PhD, FAAHMS, FAPA), NHMRC Senior Principal Research Fellow is the Director of the Melbourne Dementia Research Centre and Head of the Oxidation Biology Unit at The Florey Institute of Neuroscience & Mental Health, University of Melbourne. He has made outstanding contributions to the neuroscience field, most notably his discovery of the importance of metals and oxidative stress in neurological disease. The impact of his work has moved the field of neurodegeneration towards an appreciation for an underlying disturbance in brain metal homeostasis, and has provided insights into the pathogenesis of Alzheimer's disease (AD) as well as other brain diseases including amyotrophic lateral sclerosis, Parkinson's and Huntington's diseases.
His leadership has led to the development of new predictive tests for AD and innovative, potentially disease-modifying strategies based on his research. He is Chief Scientific Officer for the Cooperative Research Centre for Mental Health (Parkville) and Co-Director of Biomarker Development for The Australian Imaging, Biomarkers and Lifestyle Study of Ageing (AIBL). He is Professor of Neuroscience and Psychiatry at the University of Melbourne, and holds courtesy staff appointments in Psychiatry and Radiology at Massachusetts General Hospital, USA. He is Founding Scientist of Prana Biotechnology Ltd, Cogstate Ltd, and Chief Scientific Officer for Collaborative Medicinal Development P/L. As a recognised expert in his field, Prof Bush has published 493+ publications (>50,277 citations) and 28 patents, is ad hoc reviewer of 48 journals, and has delivered over 336 invited lectures (including 218 international and 27 Plenary). Bush is one of Australia's most highly cited neuroscientists and has frequently rated in the annual list of the top 1% of neuroscience researchers worldwide for high impact citations - categories Neuroscience and Behaviour (Thomson Reuters 2014-15, Clarivate Analytics 2016) and Cross-Field (Clarivate Analytics 2018-19). Fellow of the Australian Academy of Health and Medical Sciences and Member of Academia Europaea.
Managing Editor: Victoria Lee
Production Editor: Ting Xu
Respectfully Submitted by the Editorial Office of Element
